Fig. 6
From: Local delivery of accutox® synergises with immune-checkpoint inhibitors at disrupting tumor growth
AccuTOX® triggers ROS, disrupts endosomal membranes and enhances antigen presentation in cancer cells. A Analysis of ROS production using flow-cytometry-based MitoSOX™/DHE staining of cells treated with 33 μM of AccuTOX®. B Annexin-V+ staining of EL4 cells pre-treated with 5 mM NAC, 800 μM of α-tocopherol or 10 μM MitoTEMPO 1 h prior AccuTOX® treatment using the IC50 dose. C A representative flow-cytometry analysis assessing Annexin-V in response to AccuTOX® and Cyt-C co-treatment in EL4 cancer cells (left panel) and primary MSCs (right panel). D A representative cartoon depicting the antigen presentation assay using the EG.7 system. E A representative flow-cytometry analysis of H2-Kb on the surface of EG.7 treated with AccuTOX®. F Quantification of the means fluorescence intensity of the experiment shown in panel E. G Quantification of B3Z activation in response to EG.7 pre-treated with ascending doses of AccuTOX® (1, 4, 8, 16, and 32 μM). H Schematic diagram depicting the transplantation study using 1 μM AccuTOX®-treated EG.7 cells. I Volume assessment of control versus in vitro AccuTOX®-pretreated EG.7 tumors in male (circles) versus female (square) mice. J Kaplan–Meier survival curve for the experiment in panel I. For panels F and G, n = 5/group with *P < 0.05, **P < 0.01, and ***P < 0.001. For panels I and J, n = 10/group with **P < 0.01